Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)-Reference-Cited by-同舟云学术

Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)

Published:2014 Issue:1 Volume:13 Page:102
ISSN:1475-2840
Container-title:Cardiovascular Diabetology
language:en
Short-container-title:Cardiovasc Diabetol

Author:

Zinman Bernard,Inzucchi Silvio E,Lachin John M,Wanner Christoph,Ferrari Roberto,Fitchett David,Bluhmki Erich,Hantel Stefan,Kempthorne-Rawson Joan,Newman Jennifer,Johansen Odd,Woerle Hans-Juergen,Broedl Uli C

Publisher

Springer Science and Business Media LLC

Subject

Cardiology and Cardiovascular Medicine,Endocrinology, Diabetes and Metabolism

Cited by 202 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring the Phytoconstituents, Differential Pharmacology, and Interaction with Empagliflozin of Olea europaea Leaves Extracts;Indian Journal of Pharmaceutical Education and Research;2024-08-10

2. BMI variability and cardiovascular outcomes within clinical trial and real-world environments in type 2 diabetes: an IMI2 SOPHIA study;Cardiovascular Diabetology;2024-07-16

3. Effect of Qualifying Atherosclerotic Cardiovascular Disease Diagnosis Proximity on Cardiovascular Risk and Benefit of Empagliflozin in the EMPA-REG OUTCOME Trial;CJC Open;2024-07

4. Clinical pharmacokinetics and pharmacodynamics of empagliflozin in patients with heart failure;British Journal of Clinical Pharmacology;2024-06-09

5. Effects of Empagliflozin in Type 2 Diabetes With and Without Chronic Kidney Disease and Nondiabetic Chronic Kidney Disease: Protocol for 3 Crossover Randomized Controlled Trials (SiRENA Project);JMIR Research Protocols;2024-05-29